搜索到 1000 条关于 일본 경마 하는 법 WE445.TOP 경마고객 입장 인터넷경마 온라인 마권 발매 qoq 的文章

APCAACI 2013

congress, we are not only focused on the imminent problems of epidemics, cares... break through and advances in the field.We have invited numbers of world’

The 5th International Barcode of Life Conference

long way since December 2011 when we met in Adelaide for the Fourth... this website (http://dnabarcodes2013.org or http://dnabarcodes2013.csp.escience.cn) as we

2012.09.21 预测诺贝尔奖的娱乐

, Thomson Reuters citation analyst. “We recognize fundamental discoveries... Laureates have made such important contributions to science that we believe them
美元走强 辉瑞下调全年盈利预测

2015.04.30 美元走强 辉瑞下调全年盈利预测

由于美元走强,美国制药商辉瑞公司下调了全年的收入和盈利预测。然而,该制药公司公布的第一季度盈利好于预期,得益于其疫苗和抗癌药物的需求。28日上午辉瑞公司的股价在盘前交易大致持平于34.62美元。该公司2014年收入中有60%来自美国以外的国家,其2015年营收预期从445- 465亿美元下调至440-460亿美元
母亲血清含特异性抗体可降低新生儿感染链球菌风险

2013.11.26 母亲血清含特异性抗体可降低新生儿感染链球菌风险

Background. Further reduction in the group B streptococcal (GBS) disease burden in neonates in the United States awaits an additional prevention strategy, such as maternal immunization.Methods. We performed a prospective, multicenter, case-control study of 33 mothers delivering neonates with early onset GBS infection (cases), and 99 age- and ethnicity-matched mothers colonized with the same capsular polysaccharide (CPS) types delivering healthy neonates (controls). Relative risk and absolute risk were calculated for early onset disease associated with concentrations of type Ia, III, or V CPS-specific antibody in maternal serum.Results. For GBS types Ia and III, maternal CPS-specific antibody concentrations of ≥0.5 µg/mL were associated with a relative risk of approximately 0.1 (95% confidence intervals [CIs], .01-.74 and 0-.72, respectively; P = .02 for each), corresponding to a 90% risk reduction (by logistic regression). For type V, the relative risk was 0.3 (95% CI, .01-3.1), corresponding to a 70% risk reduction. By Bayesian modeling, the risk of early onset disease would decrease by 70% if maternal CPS-specific antibody concentrations for these 3 GBS types were ≥1 µg/mL.Conclusions. Maternal CPS-specific antibody serum concentrations of ≥1 μg/mL at the time of delivery appear to protect most neonates from early onset GBS type Ia and III disease.
人乳具抗HCV活性

2013.11.13 人乳具抗HCV活性

Background. Hepatitis C virus (HCV) is spread through direct contact with blood, although alternative routes of transmission may contribute to the global burden. Perinatal infection occurs in up to 5% of HCV-infected mothers, and presence of HCV RNA in breast milk has been reported. We investigated the influence of breast milk on HCV infectiousness.Methods/Results. Human breast milk reduced HCV infectivity in a dose-dependent manner. This effect was species-specific because milk from various animals did not inhibit HCV infection. Treatment of HCV with human breast milk did not compromise integrity of viral RNA or capsids but destroyed the lipid envelope. Fractionation of breast milk revealed that the antiviral activity is present in the cream fraction containing the fat. Proteolytic digestion of milk proteins had no influence on its antiviral activity, whereas prolonged storage at 4°C increased antiviral activity. Notably, pretreatment with a lipase inhibitor ablated the antiviral activity and specific free fatty acids of breast milk were antiviral.Conclusions. The antiviral activity of breast milk is linked to endogenous lipase-dependent generation of free fatty acids, which destroy the viral lipid envelope. Therefore, nursing by HCV-positive mothers is unlikely to play a major role in vertical transmission.
JID :白藜芦醇可增强替诺福韦的抗HIV-1活性

2013.09.21 JID :白藜芦醇可增强替诺福韦的抗HIV-1活性

Background. Targeting host-cell pathways to increase the potency of nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) is an important strategy for clinical investigation. Resveratrol is a natural product that inhibits cellular ribonucleotide reductase, prolonging the S phase of the cell cycle and preferentially lowering dATP levels.Methods. We performed in vitro evaluation of resveratrol on the antiviral activity of adenosine analog tenofovir (TFV) against sensitive and drug-resistant human immunodeficiency virus type 1 (HIV-1), from subtypes B and C, in primary cells.Results. Resveratrol enhanced the antiviral activity of TFV by up to 10-fold and restored susceptibility of TFV-resistant viruses. Resveratrol prevented wild-type HIV-1 from developing phenotypic resistance to TFV. Notably, resveratrol enhanced TFV activity against sensitive and resistant HIV-1 from both subtypes B and C.Conclusions. Prolonged wide-scale use of thymidine analogs in the setting of viral failure has limited the efficacy of second-line NRTI-based regimens in Africa. Moreover, the extensive use of ddI and d4T has led to high frequencies of the K65R mutation, further compromising TFV efficacy. In light of increasing resistance to commonly used NRTIs in global HIV treatment programs, targeting nucleoside biosynthesis with resveratrol, or derivatives with improved bioavailabilities, is a potential strategy to maintain, enhance, and restore susceptibility of commonly used NRTIs.
抗逆转录病毒治疗联合拉替拉韦可介导HIV-1感染者快速免疫重建

2013.09.14 抗逆转录病毒治疗联合拉替拉韦可介导HIV-1感染者快速免疫重建

Background. In treatment-naive, human immunodeficiency virus (HIV)-infected persons, combination antiretroviral therapy (cART) incorporating raltegravir (RAL) is highly effective for virologic suppression, but characteristics of immunologic recovery have not been described.Methods. We performed a 48-week substudy of 15 patients, median age 40 years, within a phase 2 randomized trial of RAL-cART in treatment-naive patients with chronic HIV infection.Results. Plasma viral load decreased from 5.2 ± 5.3 log10 HIV RNA copies/mL to 2.2 ± 2.4 log10 copies/mL at week 4, reaching <50 copies/mL at week 8 in 13 of 15 patients. Total CD4 T cells increased at week 4, as did central memory CD4 T cells in association with reduction of the immune activation markers HLA-DR and CD38 and immune exhaustion marker PD1 in CD4 and CD8 T cells. Naive CD4 T cells increased at week 24 with appearance of HIV gag-specific interleukin 2, interferon-γ, and CD107a responses in CD4 and CD8 T cells at week 48. Plasma lipopolysaccharide and soluble CD14 decreased, but at week 48 were elevated as compared to healthy volunteers. Altogether, the week 48 immune profile was more favorable in patients taking RAL-cART than in patients treated with non-RAL-cART.Conclusions. RAL in first-line treatment regimens results in rapid immune reconstitution with residual low-level microbial translocation.
 人冠状病毒229E和OC43在成年人群的发病率和临床特点相似

2013.09.12 人冠状病毒229E和OC43在成年人群的发病率和临床特点相似

Background. The incidence and clinical impact of Coronavirus (CoV) infection in elderly persons and those with underlying cardiopulmonary disease over a long duration is not well described. We determined the incidence and clinical impact of 229E and OC43 CoV in this population during four consecutive winters, and compared illnesses to influenza A, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).Methods. CoV229E and OC43 were detected by RT-PCR and serology in four adult populations under surveillance for acute respiratory illness during the winters of 1999-2003. Cohorts included young healthy adults, healthy elderly, high-risk adults with underlying cardiopulmonary disease, and a hospitalized group.Results. 398 CoV infections were identified, with annual infection rates ranging from 2.8-26% in prospective cohorts, and prevalence ranging from 3.3-11.1% in the hospitalized cohort. The incidence of infections with each strain was similar, although asymptomatic infection and viral co-infection was significantly more common with 229E than OC43 infection. Although the incidence and clinical manifestations were similar for each strain, OC43 infected subjects tended to seek more medical care as OC43 was twice as common as 229E among the hospitalized cohort.Conclusions. CoV infections in the elderly are frequent, likely causing substantial medical disease burden.
HIV和流感病毒感染与血中肺炎球菌负荷增加相关

2013.09.11 HIV和流感病毒感染与血中肺炎球菌负荷增加相关

Background. Increased pneumococcal loads are associated with severe outcomes. We determined the prevalence of pneumococcal DNA in blood specimens from patients hospitalized with acute lower respiratory tract infection and identified factors associated with invasive pneumococcal pneumonia, bacterial loads, and death.Methods. A total of 8523 patients were enrolled as part of prospective hospital-based surveillance. Blood was collected for quantitative pneumococcal (lytA) detection, and nasopharyngeal specimens were collected for detection of influenza virus and other respiratory viruses by real-time polymerase chain reaction.Results. Of 6396 cases (75%) with lytA results, 422 (7%) were positive for pneumococcal DNA. The prevalences of human immunodeficiency virus (HIV) and influenza virus were 51% (2965/5855) and 8% (485/6358), respectively. On multivariable analysis, HIV infection (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.6-3.6), influenza virus coinfection (aOR, 1.4; 95% CI, 1.2-2.1), oxygen therapy during admission (aOR, 1.6; 95% CI, 1.1-2.3) and in-hospital death (aOR, 2.1; 95% CI, 1.1-4.0) were significantly associated with increased pneumococcal load. Among lytA-positive patients, after adjustment for length of hospitalization, duration of symptoms, and oxygen therapy during admission, pneumococcal loads ≥10,000 DNA copies/mL (aOR, 3.6; 95% CI, 1.8-7.2) were associated with increased risk of death.Conclusions. HIV and influenza virus infections were associated with elevated pneumococcal loads, which, in turn, were associated with increased risk of death.
预见2020:全球处方药销售解析

2014.11.22 预见2020:全球处方药销售解析

庞大的处方药销售市场的无疑是全球的医药巨头们。EvaluatePharma推测,2020年全球处方药销售Top20公司的销售额合计可达5795亿美元,占...稳居全球处方药销售Top20公司的榜首。而凭借出色的HIV药物特许经营权和最近获批并赢得极佳预测的丙肝治疗药物Sovaldi,2020年吉利德科学

2011.12.30 SCI经验之坚持到底

We have to ask a native English speaker for writing assistance.... should be included.R: We think the cause of death should be an acute
2015 神经领域 SCI 影响因子发布 有啥重大改变

2016.06.14 2015 神经领域 SCI 影响因子发布 有啥重大改变

。临床神经病学临床神经病学相关杂志 TOP 20 中,IF 呈上升趋势的占了一多半,分数下滑的杂志只有 6 本(具体见表格 1 中红色箭头所示)。排名前 5 的杂志...,而 NEURO-ONCOLOGY 也从去年的 15 名进步到第 9。另外,今年有 4 本期刊新登 TOP 20:CEPHALALGIA(排名 13

2012.09.19 第15届欧洲神经协会联合会大会

We expect between 40,000 and 5,000 neurologists to gather in Budapest

2012.09.19 第二届国际肿瘤表观遗传学研讨会

full responsibility of the content of the abstract and we assume that all

2012.09.19 2011中国脑卒中大会暨全国心脑血管病防治管理论坛

各地市卫生局、相关医院:
近20年来,我国慢性病的发病率持续增高,已成为威胁人民群众健康的重要危险因素,其中脑血管病已是第一位的死亡原因。为降低脑卒中发生率与死亡率,探索我国慢病防控新途径,卫生部启动了脑卒中筛查与防治工程,成立了以陈竺部长为主任,马晓伟副部长、尹力副部长、王陇德院士为副主任,卫生部办公厅、规财司、疾控局、医政司、科教司、保健局等司局领导为委员的“卫生部委员会”。
由卫生部脑卒中筛查与防治工程委员会主办,卫生部医政司、疾控局、科教司、医管司、新闻宣传办公室、中华医学会、中华预防医学会、中国医院协会、中国医师协会、中国康复医学会、中华护理学会、中国老年保健医学研究会、中国医药卫生事业发展基金会协办的“2011′中国脑卒中大会”定于2011年5月12~15日在北京国家会议中心召开,届时,中国工程院与国家卫生部还将共同举办“全国心脑血管病防治管理论坛”,10位院士和6位我国心脑血管病专业领域著名专家、医院院长将发表演讲。
此次会议,从整体战略部署上,将面向基层医疗机构广泛地开展动员,沟通信息,以期提高医务人员思想认知和技术、理论水平。请各地市级卫生行政主管部门结合本地区情况,推荐5—10家具备开展脑卒中筛查与防治工作的地市级、县级医院,组织相关医务人员参加大会。同时,选择一至两家地市级城市医院,作为“卫生部脑卒中筛查与防治工程基地”候选医院。参会代表将授予国家级1类学分10分。

2012.09.19 2011 印度医药与保健行业展

2011 印度医药与保健行业展
举办方 IndianDrugManufacturers’AssociationOrbitzExhibitionsPvt.Ltd.
参展日期 2011/9/17 ~ 2011/9/19
报名截止: 2011/8/1
参展地(展馆): Gujarat University Exhibition Hall,Ahmedabad, Guja
批准单位:
主办单位: Indian Drug Manufacturers’Association,Orbitz Exhibitions Pvt. Ltd.
承办单位: 主办方指定中国销售代表处:北京知博瑞国际展览有限公司
支持协办单位: 主办方指定中国销售代表处:北京知博瑞国际展览有限公司
展会简介
展会简介: 2011 印度医药与保健行业展
展会日期:2011.9.17——19
展会地点:Gujarat University Exhibition Hall,Ahmedabad, Gujarat State,India
主办方:Indian Drug Manufacturers’Association,Orbitz Exhibitions Pvt. Ltd.
展会周期:两年一届
主办方指定中国销售代表处:北京知博瑞国际展览有限公司
展会简介:2011年即将举行的第二届印度国际医药保健展是印度著名的医药与保健行业展览会,将汇集众多制药企业、药品包装材料与机械以及生物制药的供应商、经销商,为其提供巨大的产业交流平台。
往届回顾:2009年举行的首次印度医药展取得了巨大的成功,近万名贸易商、200多名参展商参加了此次展览会,平均每天每位参展商累计吸引了近4000多名贸易商,并最终达成多项合作协议。展会期间印度许多业界知名人士参加了此次展览,并对该展会的成功举办大加赞赏。
市场简介:制药产业的产能在世界众多产业中脱颖而出,已经达到世界第三,其创造的价值已经跃升全球第14位,达200亿美元之多。印度制药产业正在以9%的速度迅猛增长,其产值到2015年预计将达500亿美元,仅Gujarat一地便贡献了占印度医药产品总出口量的22%,近一半的医药生产企业都落户在Gujarat。
参展范围、展会范围、展品范围:
? 处方药 ? 活性 药用成分(原料药)? 制药器械 ? 阿育吠陀/草本药剂? 营养保健品 / ?膳食补充剂 ? 美容产品? 兽药 ? 医疗&处理? 赋形剂 /食品添加剂 / 天然萃取物 ? 香精&香料? 药品包装材料与机械 ? 诊断试剂? 生物制药 ? 研究与测试实验室? 分析服务 ? 合同研究组织(CRO)? 实验室设备/实验室化学药品 ? 协会/媒体/刊物? 顾问 ? 药剂辅助&Utility Suppliers
参展联系:
北京知博瑞国际展览有限公司
联系人:刘晓
电话:010-62975563-812
传真:010-82967077
E-mail: expo161@spring365.net/spring1981@163.com
QQ:1794610799
MSN:spring1292011@hotmail.com
web:www.spring365.net
地址:北京市海淀区西三旗上奥世纪2号楼B座1303/1305室 100196
收费标准
收费标准: 注:特装展位请提前申请、由参展商自行设计搭建或委托组委会工程部搭建
展会现场活动
联系资料
联系人: 刘晓
公司名称: 北京知博瑞国际展览有限公司
国家或地区: 中国
省/州: 北京
城 市: 北京
联系地址: 北京市海淀区西三旗上奥世纪2号楼
邮 编:
固定电话: 010-62975563-812
传 真:
移动电话:
电子邮件:
网 址:

2012.09.19 “为伤痛包扎”——无国界医生志愿人员救援经验分享

各位医学界朋友,您好!
无国界医生将与中山大学附属第一医院合作举办名为“为伤痛包扎”的救援经验分享会。届时中国内地最先加入无国界医生的两位医务工作者-屠铮和张定宇,将亲临现场,与中山大学附属第一医院的中国医疗队成员,面对面交流分享人道救援工作。讲座的最后环节,他们还将一起接受观众的提问。
分享会将于八月三十日下午三点至五点,在中山大学附属第一医院门诊楼十七楼准时开始,我们诚挚邀请您莅临现场参加,并与无国界医生以及国家医疗队成员面对面畅所欲言。
屠铮和张定宇简介:
屠铮和张定宇是中国内地最先加入无国界医生的两位医务工作者。从2007年开始,屠铮先后在利比里亚、土库曼斯坦、斯里兰卡、南苏丹和巴基斯坦的项目,参与前线医疗及人道救援工作。张定宇此前曾作为中国医疗队一员,在阿尔及利亚和中国四川汶川地震灾区进行救援。他于2010年加入无国界医生,并于同年12月前往巴基斯坦,参与无国界医生在当地的人道救援工作。

如果查询,请联系
无国界医生广州代表处 020-8336-7085
无国界医生广州代表处 中国联络经理 赵艳平 13602491710
无国界医生广州代表处 媒体主任 曾蔚彬 13229960958

2012.09.19 NEIMS (2011新纪元国际多学科共享大会)&CNIC(首届中国神经介入大会)

为促进我国神经介入领域的发展,加强多学科间交流与合作,2011新纪元国际多学科共享大会(New Era InternationalMultidisciplinary Sharing Zhengzhou 2011)将于今年10月26日—28日在郑州中州皇冠假日酒店召开。
会议秉承“高效、交流与促进”的宗旨,构筑中美两国医师和学者在神经介入领域的交流平台,分享当前国际最先进的经验及最新的技术和器械进展。本届重点议题是基底动脉疾病的神经介入诊断与治疗。

会议主席
姜卫剑 (首都医科大学附属北京天坛医院)
Peter Rasmussen (美国克利夫兰临床医学中心)
会议执行主席
李天晓 (河南省人民医院)
组织机构
主办单位:首都医科大学附属北京天坛医院
美国克利夫兰临床医学中心
承办单位:河南省人民医院
会议基本信息
会议时间:2011年10月26日—28日(26日报到注册)
会议地点:郑州中州皇冠假日酒店
会议语言:英文

大会秘书处
学术部
吴立恒 Tel:(0371)65580265 15515893628
Fax:(0371)65580258
E-mail:dr.litianxiao88@gmail.com
会务部
郝悦希 Tel:(010)64169501-1013 13552358762
Fax:(010)64179202
E-mail:melissahaowork@yahoo.cn
小谈 BMJ 杂志 Rapid Response 发表体会

2014.05.04 小谈 BMJ 杂志 Rapid Response 发表体会

Zhang,I am sorry that we cannot consider your letter to the editor concerning... publication of the article. We received your letter in our office on January 9
上一页 1 2 3 ... 34 35 36 ... 48 49 50 下一页 到第